Janux Therapeutics (JANX) Net Cash Flow (2020 - 2026)
Janux Therapeutics (JANX) posted quarterly Net Cash Flow of -$506000.0 for Q1 2026, up 99.86% year-over-year from -$253179.5 in Q1 2025, and down 112.83% quarter-over-quarter from $3.9 million in Q4 2025.
Janux Therapeutics (JANX) Net Cash Flow (2020 - 2026) Analysis & Trends
Janux Therapeutics (JANX) has reported Net Cash Flow for 7 consecutive years, with -$506000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow rose 99.86% year-over-year to -$506000.0; the TTM figure through Mar 2026 stood at -$21.9 million (up 84.24% YoY), while the FY2025 annual figure was -$378.3 million, down 191.95% from the prior year.
- Net Cash Flow slipped to -$506000.0 in Q1 2026 per JANX's latest filing, from $3.9 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $403.9 million in Q4 2024 and bottomed at -$356.9 million in Q1 2025.
- Historically, Net Cash Flow has averaged $955647.1 across 5 years, with a median of $2.1 million in 2023.
- On a YoY basis, Net Cash Flow climbed as much as 19571.26% in 2024 and fell as far as 6018.19% in 2024.
- Janux Therapeutics' Net Cash Flow stood at -$13.3 million in 2022, then jumped by 115.41% to $2.1 million in 2023, then soared by 19571.26% to $403.9 million in 2024, then tumbled by 99.02% to $3.9 million in 2025, then sank by 112.83% to -$506000.0 in 2026.
- Business Quant data shows JANX's Net Cash Flow at -$506000.0 in Q1 2026, $3.9 million in Q4 2025, and -$4.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Janux Therapeutics | 984.58 Mn | 984.58 Mn | - | -24.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -24.06 Mn |
| Jun 30, 2026 | -24.06 Mn |
| Mar 31, 2026 | -506,000.00 |
| Mar 31, 2026 | -506,000.00 |
| Dec 31, 2025 | 3.95 Mn |
| Dec 31, 2025 | 3.95 Mn |
| Sep 30, 2025 | -4.06 Mn |
| Sep 30, 2025 | -4.06 Mn |
| Jun 30, 2025 | -21.30 Mn |
| Jun 30, 2025 | -21.30 Mn |
| Mar 31, 2025 | -356.86 Mn |
| Mar 31, 2025 | -356.86 Mn |
| Dec 31, 2024 | 403.85 Mn |
| Dec 31, 2024 | 403.85 Mn |
| Sep 30, 2024 | 12.09 Mn |
| Sep 30, 2024 | 12.09 Mn |
| Jun 30, 2024 | -198.14 Mn |
| Jun 30, 2024 | -198.14 Mn |
| Mar 31, 2024 | 193.60 Mn |
| Mar 31, 2024 | 193.60 Mn |